Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 193

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial

Open access
Motzer, Robert J, Russo, Paul, Grünwald, Viktor, Tomita, Yoshihiko, Zurawski, Bogdan, Parikh, Omi, Buti, Sebastiano, Barthélémy, Philippe, Goh, Jeffrey C, Ye, Dingwei, Lingua, Alejo, Lattouf, Jean-Baptiste, Albigès, Laurence, George, Saby, Shuch, Brian, Sosman, Jeffrey, Staehler, Michael, Vázquez Estévez, Sergio, Simsek, Burcin, Spiridigliozzi, Julia, Chudnovsky, Aleksander, Bex, Axel · 2023 · The Lancet

Abstract

Summary Background Effective adjuvant therapy for patients with resected localised renal cell carcinoma represents an unmet need, with surveillance a current standard of care. We report results from a phase 3 randomised trial (part A) assessing the efficacy and safety of adjuvant nivolumab plus ipilimumab versus placebo. Methods The double-blind, randomised, multinational, phase 3 CheckMate 914 trial (NCT03138512) enrolled patients with localised clear cell renal cell carcinoma at high risk of relapse after radical or partial nephrectomy between 4–12 weeks before randomisation. Patients were randomised (1:1) to nivolumab (240 mg) intravenously every 2 weeks for 12 doses plus ipilimumab (1 mg/kg) every 6 weeks for four doses, or matching placebo. Expected treatment period was 24 weeks, and could be continued until week 36, allowing for treatment delays. Randomisation was stratified by TNM stage and partial/radical nephrectomy. The primary endpoint was disease-free survival by blinded independent central review; safety was a secondary endpoint. Findings Between August 28, 2017, and March 16, 2021, 405 patients were randomised to nivolumab plus ipilimumab and 411 to placebo. With median follow-up of 37·0 months, median disease-free survival was not reached with nivolumab plus ipilimumab versus 50·7 months (95% CI 48·1-not estimable) with placebo (HR 0·92; 95% CI 0·71–1·19; p=0·53). A total of 33 deaths occurred in the nivolumab plus ipilimumab arm and 28 in the placebo arm. All-cause grade 3–5 adverse events occurred in 38% of patients treated with nivolumab plus ipilimumab and in 10% of patients receiving placebo; any-grade adverse events led to treatment discontinuation in 32% and 2% of patients, respectively. Four deaths were attributed to treatment with nivolumab plus ipilimumab. Interpretation Adjuvant therapy with nivolumab plus ipilimumab did not improve disease-free survival versus placebo in patients with localised renal cell carcinoma at high risk of recurrence after nephrectomy. Funding Bristol Myers Squibb and Ono Pharmaceutical.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(22)02574-0

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 193

Metadata

Authors
Motzer, R. J., Russo, P., Grünwald, V., Tomita, Y., Zurawski, B., Parikh, O., Buti, S., Barthélémy, P., Goh, J. C., Ye, D., Lingua, A., Lattouf, J.-B., Albigès, L., George, S., Shuch, B., Sosman, J., Staehler, M., Vázquez Estévez, S., Simsek, B., Spiridigliozzi, J., Chudnovsky, A., & Bex, A.
Venue
The Lancet
Publisher
Elsevier BV
Published
2023-03
Volume
401
Issue
10379
Pages
821-832
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W4319660667
Cited by
193
References
4
FWCI
30.50
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial. https://app.cochat.ai/papers/10.1016/s0140-6736(22)02574-0
The paper
Motzer, R. J., Russo, P., Grünwald, V., Tomita, Y., Zurawski, B., Parikh, O., Buti, S., Barthélémy, P., Goh, J. C., Ye, D., Lingua, A., Lattouf, J.-B., Albigès, L., George, S., Shuch, B., Sosman, J., Staehler, M., Vázquez Estévez, S., Simsek, B., . . . Bex, A. (2023). Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial. The Lancet. https://doi.org/10.1016/s0140-6736(22)02574-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.